Allergic Rhinitis
📧 Sign up to get email alerts when something new happens for Allergic Rhinitis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2018-12-07FDA Approved: OLOPATADINE HYDROCHLORIDE — Original Application (Alembic Pharmaceuticals Inc.)
FDA approved Alembic Pharmaceuticals' original ANDA for olopatadine hydrochloride, a generic antihistamine indicated for allergic conjunctiv…
-
FDA approval · 2018-11-30FDA Approved: DIPHENHYDRAMINE HYDROCHLORIDE — Supplemental Application (Armas Pharmaceuticals Inc.)
FDA approved a supplemental application for diphenhydramine hydrochloride from Armas Pharmaceuticals Inc.
-
FDA approval · 2018-11-20FDA Approved: ALLERGY RELIEF 24HR — Original Application (VELOCITY PHARMA LLC)
FDA approved the original application for Allergy Relief 24HR (levocetirizine dihydrochloride) from Velocity Pharma LLC. It is a generic ant…
-
FDA approval · 2018-11-16FDA Approved: ALLERGY AND SINUS RELIEF — Original Application (Kroger Company)
FDA approved Kroger's original application for an OTC allergy and sinus relief product containing cetirizine hydrochloride and pseudoephedri…
-
FDA approval · 2018-10-17FDA Approved: NASACORT ALLERGY 24HR — Supplemental Application (Chattem, Inc.)
FDA approved a supplemental application for Nasacort Allergy 24HR (triamcinolone acetonide) by Chattem, Inc., updating the product labeling …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA label_change · 2018-10-11FDA Approved: CHILDRENS ZYRTEC — Supplemental Application (Kenvue Brands LLC)
FDA approved a supplemental labeling action for Children's Zyrtec (cetirizine hydrochloride) by Kenvue Brands LLC. The action updates the pr…
-
CLINICAL_TRIALS trial_result · 2018-10-11Clinical Trial Update: Clinical Efficacy and Safety of a Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis [Phase 3]
Phase 3 trial evaluating subcutaneous immunotherapy gpASIT+ for grass pollen-induced allergic rhinoconjunctivitis completed.
-
FDA approval · 2018-10-03FDA Approved: CLARITIN — Supplemental Application (Bayer HealthCare LLC)
FDA approved a supplemental application for Claritin (loratadine) from Bayer HealthCare LLC. The action approves changes to the product's la…
-
FDA approval · 2018-09-06FDA Approved: DYMISTA — Supplemental Application (Viatris Specialty LLC)
FDA approves a supplemental application for DYMISTA (azelastine hydrochloride and fluticasone propionate) submitted by Viatris Specialty LLC…
-
CLINICAL_TRIALS trial_result · 2018-08-22Clinical Trial Update: Efficacy and Adverse Effects of Prapchompoothaweep Remedy and Loratadine for Treatment in AR Patients [Phase 2]
Phase 2 clinical trial evaluating the efficacy and safety of Prapchompoothaweep Remedy with loratadine for allergic rhinitis and associated …
-
FDA approval · 2018-08-22FDA Approved: DIPHENHYDRAMINE HYDROCHLORIDE — Original Application (Armas Pharmaceuticals Inc.)
FDA approved the original generic application for diphenhydramine hydrochloride from Armas Pharmaceuticals, making a generic diphenhydramine…
-
CLINICAL_TRIALS trial_result · 2018-08-20Clinical Trial Update: Safety and Efficacy Study of Intralymphatic Allergen-specific Immunotherapy [Phase 2, Phase 3]
Clinical trial update for intralymphatic allergen-specific immunotherapy shows safety and efficacy data from Phase 2 and Phase 3 studies in …
-
CLINICAL_TRIALS trial_result · 2018-08-16Clinical Trial Update: Randomized Evaluation of Ten Allergy Skin Prick Test Devices [NA]
Completed randomized evaluation of ten allergy skin prick test devices; results posted in 2018.
-
FDA approval · 2018-08-13FDA Approved: FEXOFENADINE HYDROCHLORIDE — Original Application (Pioneer Life Sciences, LLC)
FDA approved a generic version of fexofenadine hydrochloride from Pioneer Life Sciences, LLC under an original ANDA, indicated for allergic …
-
CLINICAL_TRIALS trial_result · 2018-08-08Clinical Trial Update: Safety, Tolerability and Efficacy of the Depigmented Modified Allergen Extract of Two Mites in Subjects With Allergic Rhinitis or Rhinoconjunctivitis, With Controlled Allergic Asthma [Phase 2]
Phase 2 trial evaluating safety, tolerability and efficacy of a depigmented modified allergen extract from two mites in subjects with allerg…
-
FDA approval · 2018-07-31FDA Approved: CLARITIN-D 12 HOUR — Supplemental Application (Bayer HealthCare LLC.)
FDA approved a supplemental application for Claritin-D 12 Hour (loratadine and pseudoephedrine sulfate) to update and expand the product lab…
-
FDA approval · 2018-07-31FDA Approved: CLARITIN-D 24 HOUR — Supplemental Application (Bayer HealthCare LLC.)
FDA approved a supplemental application for CLARITIN-D 24 HOUR (loratadine and pseudoephedrine sulfate) from Bayer HealthCare LLC.
-
FDA approval · 2018-07-31FDA Approved: MONTELUKAST SODIUM — Original Application (Torrent Pharmaceuticals Limited)
FDA approves Torrent Pharmaceuticals Limited's original ANDA for montelukast sodium (generic montelukast).
-
FDA approval · 2018-07-30FDA Approved: MONTELUKAST — Supplemental Application (XLCare Pharmaceuticals Inc.)
FDA approved a supplemental application for montelukast from XLCare Pharmaceuticals Inc. under ANDA 202843.
-
FDA approval · 2018-07-26FDA Approved: MONTELUKAST — Supplemental Application (Sandoz Inc)
The FDA approved a supplemental application for Montelukast from Sandoz Inc, authorizing the generic montelukast product under an ANDA.
-
CLINICAL_TRIALS trial_result · 2018-07-26Clinical Trial Update: Evaluation and Validation of Novel Diagnostic Tool for Allergists (AbioSCOPE)
This clinical trial update reports on the evaluation and validation of a novel diagnostic tool, AbioSCOPE, intended for allergists, in patie…
-
FDA approval · 2018-07-23FDA Approved: CLARITIN REDITABS — Supplemental Application (Bayer Healthcare LLC.)
FDA approved a supplemental application for Claritin RediTabs (loratadine) from Bayer, resulting in a labeling update for this product.
-
FDA approval · 2018-07-23FDA Approved: MONTELUKAST SODIUM — Supplemental Application (Rising Pharma Holdings, Inc.)
FDA approved a supplemental application for Montelukast Sodium from Rising Pharma Holdings, Inc., enabling the marketing of the generic prod…
-
FDA approval · 2018-07-23FDA Approved: MONTELUKAST SODIUM — Supplemental Application (Rising Pharma Holdings, Inc.)
FDA approved a supplemental application for a generic Montelukast sodium product from Rising Pharma Holdings, Inc.
-
FDA approval · 2018-07-23FDA Approved: MONTELUKAST SODIUM — Supplemental Application (Lannett Company, Inc.)
FDA approved a supplemental application for Montelukast Sodium from Lannett Company, Inc., adding regulatory approval for an additional gene…